Video
Incorporating genetic testing and counseling for prostate cancer into clinical practice
Author(s):
“I think this is an area that needs to be really personalized to each clinical practice,” says Alicia K. Morgans, MD, MPH.
Video Player is loading.
In this video, Alicia K. Morgans, MD, MPH, discusses the practices she implements regarding germline and somatic testing in patients with advanced prostate cancer. These ideas were focused on in her presentation, “Advanced disease: incorporating molecular markers and genomic studies into therapy,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morgans is a genitourinary medical oncologist and medical director of the Survivorship Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Related Videos
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
Dr. Vince on evaluation of prostate cancer polygenic risk scores
Related Content
